精品文档---下载后可任意编辑200 例晚期非小细胞肺癌化疗疗效及预后影响因素的分析的开题报告标题:200 例晚期非小细胞肺癌化疗疗效及预后影响因素的分析摘要:目的:本讨论旨在分析 200 例晚期非小细胞肺癌(NSCLC)患者化疗疗效及影响其预后的因素,为临床提供参考和指导。方法:回顾性分析 2024 年至 2024 年在我们医院接受化疗治疗的NSCLC 患者资料。收集病例的临床资料、病理资料,包括性别、年龄、病理分型、肿瘤分期、化疗方案、治疗反应以及生存期等。结果:本讨论共纳入 200 例 NSCLC 患者,其中男性 130 例,女性70 例;年龄范围为 31 至 88 岁,平均年龄为 61 岁。病理学分型以腺癌(62.5%)为主,在分期方面,分期Ⅲ期和Ⅳ期患者占比最高,分别为40%和 32.5%。化疗方案以卡铂+依托泊苷(33%)为主。治疗反应共分为 4 个级别,完全缓解(CR)、部分缓解(PR)、病情稳定(SD)和病情进展(PD),其中 CR 和 PR 次数最多,分别为 67 例和 75 例,有效率为 71%。生存分析显示,患者的中位生存期为 12.6 个月。年龄、性别、病理分型、肿瘤分期、治疗方案对生存期有影响。结论:本讨论结果显示,化疗对晚期 NSCLC 患者具有一定的疗效,并且影响因素较多,应根据患者的具体情况进行个体化治疗和预后评估。关键词:非小细胞肺癌、化疗、疗效、预后Abstract:Objective: The aim of this study was to analyze the efficacy of chemotherapy and prognostic factors in 200 patients with advanced non-small cell lung cancer (NSCLC), and to provide a reference and guidance for clinical practice.Methods: A retrospective analysis was performed on the data of NSCLC patients who underwent chemotherapy treatment in our hospital from 2024 to 2024. Clinical and pathological data were collected, including gender, age, pathological type, tumor stage, chemotherapy regimen, treatment response and survival.Results: A total of 200 NSCLC patients were included in this study, including 130 males and 70 females, with an age 精品文档---下载后可任意编辑range of 31 to 88 years (mean age: 61 years). Adenocarcinoma (62.5%) was the predominant ...